FCM
BMRN icon

Flinton Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Flinton Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-128
Closed -$11K – 884
2019
Q1 		$11K Buy
+128
New +$11.9K ﹤0.01% 863

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Flinton Capital Management's BMRN Position: Q2 2019 in Review

Flinton Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 128 shares — an estimated $11K sold.

Flinton Capital Management first reported a position in BMRN in Q1 2019 and held it in 1 quarter. The position peaked at $11K in Q1 2019. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

  • Flinton Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Flinton Capital Management sold 128 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $11K.
  • Flinton Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Flinton Capital Management's BioMarin Pharmaceuticals position peaked at $11K in Q1 2019.
  • 482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Flinton Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.